시장보고서
상품코드
1267363

세계의 부신피질 자극 호르몬 시장 : 규모, 점유율, 동향 분석, 기회 및 예측(2019-2029년) : 기원별, 적응증별, 유통 채널별, 지역별

Adrenocorticotropic Hormone Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Source : By Indication ; By Distribution Channel ; By Region

발행일: | 리서치사: Blueweave Consulting | 페이지 정보: 영문 400 Pages | 배송안내 : 2-3일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 부신피질 자극 호르몬 시장 규모는 2022년 13억 9,000만 달러에 달했습니다. 향후 2023년부터 2029년까지 6.48%의 놀라운 CAGR로 확대되어 2029년에는 21억 4,000만 달러에 달할 것으로 예상됩니다.

본 보고서는 세계 부신피질 자극 호르몬(Adrenocorticotropic Hormone) 시장에 대해 조사했으며, 시장 개요와 함께 기원별, 적응증별, 유통 채널별, 지역별 동향, 경쟁 상황, 시장 진출기업 프로파일 등의 정보를 전해드립니다.

목차

제1장 조사 프레임워크

제2장 주요 요약

제3장 세계의 부신피질 자극 호르몬(ACTH) 시장 인사이트

  • 업계 밸류체인 분석
  • DROC 분석
    • 촉진요인
    • 억제요인
    • 기회
    • 과제
  • 기술 진보/최근 개발
  • 규제 프레임워크
  • Porter's Five Forces 분석

제4장 세계의 부신피질 자극 호르몬(ACTH) 시장 개요

  • 시장 규모와 예측, 2019년-2029년
  • 시장 점유율과 예측
    • 유래 별
      • 자연
      • 합성
    • 적응증별
      • 류머티즘과
      • 신경과
      • 네프로제 증후군
      • 안과
      • 기타
    • 유통 채널별
      • 원내 약국
      • 소매 약국
      • 온라인 약국
    • 지역별
      • 북미
      • 유럽
      • 아시아태평양
      • 라틴아메리카
      • 중동 및 아프리카

제5장 북미 부신피질 자극 호르몬(ACTH) 시장

제6장 유럽 부신피질 자극 호르몬(ACTH) 시장

제7장 아시아태평양 피질 자극 호르몬(ACTH) 시장

제8장 라틴아메리카 피질 자극 호르몬(ACTH) 시장

제9장 중동 및 아프리카 부신피질 자극 호르몬(ACTH) 시장

제10장 경쟁 구도

제11장 세계의 부신피질 자극 호르몬(ACTH) 시장에 대한 COVID-19의 영향

제12장 기업 개요

  • Novartis International AG
  • Pfizer Inc.
  • Mallinckrodt Pharmaceuticals
  • Hikma Pharmaceuticals PLC
  • West-Ward Pharmaceuticals Corp.
  • Horizon Therapeutics plc
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • Ferring Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Aspen Pharmacare Holdings Limited
  • Amphastar Pharmaceuticals, Inc.
  • EMD Serono, Inc.
  • Mylan N.V.
  • Taj Pharmaceuticals Ltd.
  • 기타

제13장 주요 전략적 추천 사항

제14장 조사 방법

LSH 23.05.12

Global Adrenocorticotropic Hormone Market Size Set to Cross USD 2.1 Billion by 2029.

Global adrenocorticotropic hormone market is flourishing because of increasing focus on providing care to growing geriatric population across countries and rising prevalence of disorders related to the adrenal gland.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated global adrenocorticotropic hormone (ACTH) market size at USD 1.39 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects global adrenocorticotropic hormone market size to grow at a significant CAGR of 6.48% reaching a value of USD 2.14 billion by 2029. Major growth drivers for global adrenocorticotropic hormone market include rising incidence of adrenal insufficiency and autoimmune diseases, growing awareness about early diagnosis and treatment, and the availability of advanced diagnostic techniques. In particular, autoimmune and inflammatory diseases, such as rheumatoid arthritis, lupus, and multiple sclerosis, have contributed to the growth of the ACTH market. As these conditions require long-term management, ACTH is often used as a treatment option to manage symptoms. Moreover, the availability of advanced diagnostic techniques, such as immunoassays, radioimmunoassay, and ELISA, has increased the demand for ACTH testing. These techniques enable early diagnosis of adrenal insufficiency, which is another factor driving the growth of the ACTH market. The popularity of biologics for the treatment of autoimmune and inflammatory diseases due to their high specificity and low toxicity has also played a significant role. As ACTH is a biologic hormone used to treat these conditions, the increasing adoption of biologics is expected to further drive the growth of the ACTH market. However, high cost of treatment and side effects associated with ACTH therapy are anticipated to restrain the growth of the market during the period in analysis.

Global Adrenocorticotropic Hormone Market - Overview:

Adrenocorticotropic hormone (ACTH) is a hormone produced by the pituitary gland that stimulates the production and release of cortisol from the adrenal glands. Cortisol is a steroid hormone that is important in regulating various bodily functions such as metabolism, immune response, and stress response. ACTH is primarily used in the diagnosis of adrenal insufficiency and as a treatment for certain autoimmune and inflammatory conditions such as multiple sclerosis and rheumatoid arthritis.

Impact of COVID-19 on Global Adrenocorticotropic Hormone Market

COVID-19 had a dual impact on the global adrenocorticotropic hormone (ACTH) market. The pandemic led to disruptions in supply chains, decreased patient visits to healthcare facilities, and delays in clinical trials, all of which have impacted the ACTH market. On the one hand, the pandemic has led to an increased demand for ACTH therapy in the treatment of severe COVID-19 cases. ACTH therapy has been used as an adjunctive treatment for COVID-19 patients who require mechanical ventilation and are at risk of developing acute respiratory distress syndrome (ARDS). This has led to an increased demand for ACTH products in certain regions. On the other, the pandemic led to a decrease in non-COVID-19-related ACTH therapy due to the decreased patient visits to healthcare facilities. The lockdowns and travel restrictions also led to disruptions in the supply chain, which impacted the availability of ACTH products. Also, delays in clinical trials due to the pandemic impacted the development of new ACTH products and may delay the approval of new treatments.

Global Adrenocorticotropic Hormone Market - By Distribution Channel:

Based on distribution channel, global adrenocorticotropic hormone market is divided into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies segments. The online pharmacies segment holds the dominant position in the global Adrenocorticotropic Hormone (ACTH) market, as they offer the convenience of ordering medication from home, eliminating the need to visit a pharmacy. The online pharmacies have a wider reach compared to traditional pharmacies, catering to customers from different locations, including remote areas. Also, they are cost-effective, often offering lower prices for medication and frequently providing discounts and other promotional offers. Lastly, the increasing adoption of e-commerce globally has contributed to the popularity of online pharmacies, as people become more comfortable with buying products online.

Competitive Landscape:

Major players operating in global adrenocorticotropic hormone market include: Novartis International AG, Pfizer Inc., Mallinckrodt Pharmaceuticals, Hikma Pharmaceuticals PLC, West-Ward Pharmaceuticals Corp., Horizon Therapeutics plc, Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., Ferring Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Aspen Pharmacare Holdings Limited, Amphastar Pharmaceuticals, Inc., EMD Serono, Inc., Mylan N.V., and Taj Pharmaceuticals Ltd. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Adrenocorticotropic Hormone Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Adrenocorticotropic Hormone Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Adrenocorticotropic Hormone (ACTH) Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. The increasing prevalence of disorders related to the adrenal gland
      • 3.2.1.2. Rising geriatric population worldwide
    • 3.2.2. Restraints
      • 3.2.2.1. Excessive cost of treatment
      • 3.2.2.2. Side effects associated with ACTH therapy
    • 3.2.3. Opportunities
      • 3.2.3.1. The development of novel therapies
      • 3.2.3.2. Increasing demand for personalized medicine
    • 3.2.4. Challenges
      • 3.2.4.1. Stringent regulatory requirements and the increasing competition from alternative therapies.
  • 3.3. Technology Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Adrenocorticotropic Hormone (ACTH) Market Overview

  • 4.1. Market Size & Forecast, 2019-2029
    • 4.1.1. By Value (USD Million)
  • 4.2. Market Share and Forecast
    • 4.2.1. By Source
      • 4.2.1.1. Natural
      • 4.2.1.2. Synthetic
    • 4.2.2. By Indication
      • 4.2.2.1. Rheumatology
      • 4.2.2.2. Neurology
      • 4.2.2.3. Nephrotic Syndrome
      • 4.2.2.4. Ophthalmology
      • 4.2.2.5. Others
    • 4.2.3. By Distribution Channel
      • 4.2.3.1. Hospital Pharmacies
      • 4.2.3.2. Retail Pharmacies
      • 4.2.3.3. Online Pharmacies
    • 4.2.4. By Region
      • 4.2.4.1. North America
      • 4.2.4.2. Europe
      • 4.2.4.3. Asia Pacific (APAC)
      • 4.2.4.4. Latin America (LATAM)
      • 4.2.4.5. Middle East and Africa (MEA)

5. North America Adrenocorticotropic Hormone (ACTH) Market

  • 5.1. Market Size & Forecast, 2019-2029
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Source
    • 5.2.2. By Indication
    • 5.2.3. By Distribution Channel
    • 5.2.4. By Country
      • 5.2.4.1. United States
      • 5.2.4.1.1. By Source
      • 5.2.4.1.2. By Indication
      • 5.2.4.1.3. By Distribution Channel
      • 5.2.4.2. Canada
      • 5.2.4.2.1. By Source
      • 5.2.4.2.2. By Indication
      • 5.2.4.2.3. By Distribution Channel

6. Europe Adrenocorticotropic Hormone (ACTH) Market

  • 6.1. Market Size & Forecast, 2019-2029
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Source
    • 6.2.2. By Indication
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
      • 6.2.4.1. Germany
      • 6.2.4.1.1. By Source
      • 6.2.4.1.2. By Indication
      • 6.2.4.1.3. By Distribution Channel
      • 6.2.4.2. United Kingdom
      • 6.2.4.2.1. By Source
      • 6.2.4.2.2. By Indication
      • 6.2.4.2.3. By Distribution Channel
      • 6.2.4.3. Italy
      • 6.2.4.3.1. By Source
      • 6.2.4.3.2. By Indication
      • 6.2.4.3.3. By Distribution Channel
      • 6.2.4.4. France
      • 6.2.4.4.1. By Source
      • 6.2.4.4.2. By Indication
      • 6.2.4.4.3. By Distribution Channel
      • 6.2.4.5. Spain
      • 6.2.4.5.1. By Source
      • 6.2.4.5.2. By Indication
      • 6.2.4.5.3. By Distribution Channel
      • 6.2.4.6. Belgium
      • 6.2.4.6.1. By Source
      • 6.2.4.6.2. By Indication
      • 6.2.4.6.3. By Distribution Channel
      • 6.2.4.7. Russia
      • 6.2.4.7.1. By Source
      • 6.2.4.7.2. By Indication
      • 6.2.4.7.3. By Distribution Channel
      • 6.2.4.8. The Netherlands
      • 6.2.4.8.1. By Source
      • 6.2.4.8.2. By Indication
      • 6.2.4.8.3. By Distribution Channel
      • 6.2.4.9. Rest of Europe
      • 6.2.4.9.1. By Source
      • 6.2.4.9.2. By Indication
      • 6.2.4.9.3. By Distribution Channel

7. Asia-Pacific Adrenocorticotropic Hormone (ACTH) Market

  • 7.1. Market Size & Forecast, 2019-2029
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Source
    • 7.2.2. By Indication
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
      • 7.2.4.1. China
      • 7.2.4.1.1. By Source
      • 7.2.4.1.2. By Indication
      • 7.2.4.1.3. By Distribution Channel
      • 7.2.4.2. India
      • 7.2.4.2.1. By Source
      • 7.2.4.2.2. By Indication
      • 7.2.4.2.3. By Distribution Channel
      • 7.2.4.3. Japan
      • 7.2.4.3.1. By Source
      • 7.2.4.3.2. By Indication
      • 7.2.4.3.3. By Distribution Channel
      • 7.2.4.4. South Korea
      • 7.2.4.4.1. By Source
      • 7.2.4.4.2. By Indication
      • 7.2.4.4.3. By Distribution Channel
      • 7.2.4.5. Australia & New Zealand
      • 7.2.4.5.1. By Source
      • 7.2.4.5.2. By Indication
      • 7.2.4.5.3. By Distribution Channel
      • 7.2.4.6. Indonesia
      • 7.2.4.6.1. By Source
      • 7.2.4.6.2. By Indication
      • 7.2.4.6.3. By Distribution Channel
      • 7.2.4.7. Malaysia
      • 7.2.4.7.1. By Source
      • 7.2.4.7.2. By Indication
      • 7.2.4.7.3. By Distribution Channel
      • 7.2.4.8. Singapore
      • 7.2.4.8.1. By Source
      • 7.2.4.8.2. By Indication
      • 7.2.4.8.3. By Distribution Channel
      • 7.2.4.9. Vietnam
      • 7.2.4.9.1. By Source
      • 7.2.4.9.2. By Indication
      • 7.2.4.9.3. By Distribution Channel
      • 7.2.4.10. Rest of APAC
      • 7.2.4.10.1. By Source
      • 7.2.4.10.2. By Indication
      • 7.2.4.10.3. By Distribution Channel

8. Latin America Adrenocorticotropic Hormone (ACTH) Market

  • 8.1. Market Size & Forecast, 2019-2029
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Source
    • 8.2.2. By Indication
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
      • 8.2.4.1. Brazil
      • 8.2.4.1.1. By Source
      • 8.2.4.1.2. By Indication
      • 8.2.4.1.3. By Distribution Channel
      • 8.2.4.2. Mexico
      • 8.2.4.2.1. By Source
      • 8.2.4.2.2. By Indication
      • 8.2.4.2.3. By Distribution Channel
      • 8.2.4.3. Argentina
      • 8.2.4.3.1. By Source
      • 8.2.4.3.2. By Indication
      • 8.2.4.3.3. By Distribution Channel
      • 8.2.4.4. Peru
      • 8.2.4.4.1. By Source
      • 8.2.4.4.2. By Indication
      • 8.2.4.4.3. By Distribution Channel
      • 8.2.4.5. Rest of LATAM
      • 8.2.4.5.1. By Source
      • 8.2.4.5.2. By Indication
      • 8.2.4.5.3. By Distribution Channel

9. Middle East & Africa Adrenocorticotropic Hormone (ACTH) Market

  • 9.1. Market Size & Forecast, 2019-2029
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Source
    • 9.2.2. By Indication
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
      • 9.2.4.1. Saudi Arabia
      • 9.2.4.1.1. By Source
      • 9.2.4.1.2. By Indication
      • 9.2.4.1.3. By Distribution Channel
      • 9.2.4.2. UAE
      • 9.2.4.2.1. By Source
      • 9.2.4.2.2. By Indication
      • 9.2.4.2.3. By Distribution Channel
      • 9.2.4.3. Qatar
      • 9.2.4.3.1. By Source
      • 9.2.4.3.2. By Indication
      • 9.2.4.3.3. By Distribution Channel
      • 9.2.4.4. Kuwait
      • 9.2.4.4.1. By Source
      • 9.2.4.4.2. By Indication
      • 9.2.4.4.3. By Distribution Channel
      • 9.2.4.5. South Africa
      • 9.2.4.5.1. By Source
      • 9.2.4.5.2. By Indication
      • 9.2.4.5.3. By Distribution Channel
      • 9.2.4.6. Nigeria
      • 9.2.4.6.1. By Source
      • 9.2.4.6.2. By Indication
      • 9.2.4.6.3. By Distribution Channel
      • 9.2.4.7. Algeria
      • 9.2.4.7.1. By Source
      • 9.2.4.7.2. By Indication
      • 9.2.4.7.3. By Distribution Channel
      • 9.2.4.8. Rest of MEA
      • 9.2.4.8.1. By Source
      • 9.2.4.8.2. By Indication
      • 9.2.4.8.3. By Distribution Channel

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Adrenocorticotropic Hormone (ACTH) Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Adrenocorticotropic Hormone (ACTH) Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 12.1. Novartis International AG
  • 12.2. Pfizer Inc.
  • 12.3. Mallinckrodt Pharmaceuticals
  • 12.4. Hikma Pharmaceuticals PLC
  • 12.5. West-Ward Pharmaceuticals Corp.
  • 12.6. Horizon Therapeutics plc
  • 12.7. Sun Pharmaceutical Industries Ltd.
  • 12.8. Merck & Co., Inc.
  • 12.9. Ferring Pharmaceuticals
  • 12.10. Teva Pharmaceutical Industries Ltd.
  • 12.11. Aspen Pharmacare Holdings Limited
  • 12.12. Amphastar Pharmaceuticals, Inc.
  • 12.13. EMD Serono, Inc.
  • 12.14. Mylan N.V.
  • 12.15. Taj Pharmaceuticals Ltd.
  • 12.16. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumptions & Limitations
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제